Lessons from oncology to understand and treat pulmonary hypertension.
Pulmonary artery hypertension (PAH) is now considered to be a proliferative disorder characterised by unexplained proliferation of pulmonary artery smooth muscle cells (PA-SMCs) and pulmonary artery endothelial cells (PA-ECs). An abnormal phenotype of PA-SMCs and PA-ECs has been described in PAH and some analogies now appear between pulmonary vascular cells from patients with PAH and cancer cells. Such analogies are discussed here with respect to essential hallmarks of cancer cells and with the hope that new treatments targeted at one or more of these cancer cell abnormalities may be appropriate for PAH.
Adnot
S
S
INSERM U841 and Département de Physiologie, Hôpital H Mondor, AP-HP, Créteil, France. serge.adnot@creteil.inserm.fr
Eddahibi
S
S
D017209:Apoptosis; D002455:Cell Division; D006131:Growth Inhibitors / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*
D006131:Growth Inhibitors; D006133:Growth Substances